Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F15%3A00085026" target="_blank" >RIV/00216224:14740/15:00085026 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/15:00063663
Result on the web
<a href="http://download.springer.com/static/pdf/372/art%253A10.1007%252Fs12185-015-1793-1.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12185-015-1793-1&token2=exp=1448961063~acl=%2Fstatic%2Fpdf%2F372%2Fart%25253A10.1007%25252Fs12185-015-17" target="_blank" >http://download.springer.com/static/pdf/372/art%253A10.1007%252Fs12185-015-1793-1.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12185-015-1793-1&token2=exp=1448961063~acl=%2Fstatic%2Fpdf%2F372%2Fart%25253A10.1007%25252Fs12185-015-17</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s12185-015-1793-1" target="_blank" >10.1007/s12185-015-1793-1</a>

Result language
angličtina
Original language name
Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults
Original language description
Thrombopoietin-receptor agonists (TPO-RAs) are highly effective in immune thrombocytopenia (ITP). Recently, reports of sustained remission after TPO-RA discontinuation in adult ITP have been reported. We aimed to describe the subset of patients in whom TPO-RA therapy may induce a durable response. We retrospectively analyzed all of our adult ITP patients treated with TPO-RAs, and focused on patients with discontinued TPO-RA therapy due to treatment response. Forty-six relapsed or refractory ITP patientswere treated with TPO-RAs. In 11 of these cases, TPO-RA therapy (seven romiplostim; four eltrombopag) was stopped after achieving treatment response. No side effects of TPO-RAs were observed. These patients were pretreated with 1-3 therapy lines plus splenectomy in six patients prior to TPO-RA administration. None of these patients experienced disease relapse after therapy discontinuation over a median follow-up of 33 months (16-54).
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/ED1.1.00%2F02.0068" target="_blank" >ED1.1.00/02.0068: Central european institute of technology</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)